MS drug ofatumumab may shield brain cells from immune attack
NCT ID NCT05171972
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This study looked at blood samples from 40 people with relapsing-remitting multiple sclerosis (MS) before and after 6 months of treatment with ofatumumab (Kesimpta). Researchers tested whether immune cells from treated patients were less harmful to mouse brain cells grown in a lab dish. The goal was to understand how the drug might protect the brain, not to directly treat patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING REMITTING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Southern California
Los Angeles, California, 90089, United States
Conditions
Explore the condition pages connected to this study.